文献速递中毒与环境急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

药物中毒大剂量胰岛素治疗后胰岛素与C肽系列浓度:连续病例系列

Serial insulin and C-peptide concentrations following high-dose insulin for the treatment of drug poisoning: a consecutive case series.
PubMed 文献 · Clin Toxicol (Phila) · 2026-02-05
一句话结论药物中毒接受大剂量胰岛素治疗后,胰岛素表观消除半衰期中位数1.8小时,高胰岛素血症多在停药24小时内缓解,系列C肽监测可能指导葡萄糖减量。

该连续病例系列纳入10例接受大剂量胰岛素治疗的中毒患者,停药后系列监测胰岛素和C肽浓度。未发生低血糖,胰岛素表观消除半衰期中位数1.8小时(IQR 1.4-4.0小时,范围1.23-9.8小时),最长者见于合并2型糖尿病及急性肾损伤的患者。尽管存在高胰岛素血症,C肽与血糖浓度同步变化,C肽多在已建立的参考范围内,提示葡萄糖补充大多未过量。高胰岛素血症通常在停药24小时内缓解,系列C肽监测可能有助于识别葡萄糖减量期间的过度碳水化合物补充。

要点

  • 10例中毒患者停用大剂量胰岛素后未发生低血糖,胰岛素表观消除半衰期中位数1.8小时(IQR 1.4-4.0小时,范围1.23-9.8小时)。
  • 最长半衰期见于合并2型糖尿病且发生急性肾损伤的患者,但作者认为半衰期未受胰岛素剂量、疗程或肾脏疾病影响。
  • 尽管存在高胰岛素血症,C肽与血糖浓度同步变化,C肽多在已建立的参考范围内,提示葡萄糖补充大多未过量。
  • 高胰岛素血症通常在停用大剂量胰岛素后24小时内缓解,系列C肽监测可能有助于指导葡萄糖减量。
  • 5例发生急性肾损伤,其中3例接受连续肾脏替代治疗;无病例接受奥曲肽治疗。

适用人群与场景

  • 接受大剂量胰岛素治疗的中毒患者,连续病例系列共10例,其中1例有既往2型糖尿病。

处置流程与药物剂量

  • 停用大剂量胰岛素后系列测量胰岛素和C肽浓度,用于指导葡萄糖减量及确认高胰岛素血症缓解。
  • 高胰岛素血症通常在停用大剂量胰岛素后24小时内缓解。

研究设计与关键结果

  • 连续病例系列纳入10例接受大剂量胰岛素治疗的中毒患者,停药后系列测量胰岛素和C肽浓度。
  • 停用大剂量胰岛素后未发生低血糖。
  • 胰岛素表观消除半衰期中位数1.8小时(IQR 1.4-4.0小时;范围1.23-9.8小时)。
  • 最长半衰期见于合并2型糖尿病且发生急性肾损伤的患者。
  • 5例发生急性肾损伤,其中3例接受连续肾脏替代治疗。
  • 尽管存在高胰岛素血症,C肽与血糖浓度同步变化,C肽多在已建立的参考范围内,提示葡萄糖补充大多未过量。
  • 无病例接受奥曲肽治疗。

证据类型、等级与局限

  • 证据类型:连续病例系列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,系列测量胰岛素和C肽浓度可能指导临床决策,包括葡萄糖减量和确认高胰岛素血症缓解。
  • 作者认为,在葡萄糖减量期间,系列C肽浓度监测可能识别过度碳水化合物补充。
  • 作者提出,未来研究应评估糖尿病和肾脏疾病等合并症如何影响胰岛素清除。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: High-dose insulin is a treatment for poisoning-induced cardiogenic shock. There is a risk of hypoglycaemia after discontinuing high-dose insulin due to persistent hyperinsulinaemia. The pharmacokinetics of insulin after discontinuing high-dose insulin are poorly defined, with previous publications reporting prolonged elimination half-lives (up to 18.8 h).

METHODS: We conducted a consecutive case series in poisoned patients treated with high-dose insulin. Serial insulin and C-peptide concentrations were measured after discontinuing high-dose insulin. The apparent elimination half-life of insulin was calculated using non-linear regression or simplified pharmacokinetic methods when data were limited.

RESULTS: We identified 10 patients. One case had pre-existing type 2 diabetes mellitus. Five cases developed acute kidney injury, and three of these cases were treated with continuous kidney replacement therapy. Hypoglycaemia did not occur after discontinuing high-dose insulin. The median apparent elimination half-life of insulin was 1.8 h (IQR 1.4-4.0 h; range 1.23-9.8 h). The longest half-life was in the patient with type 2 diabetes mellitus who also developed acute kidney injury. C-peptide and blood glucose concentrations varied together despite hyperinsulinaemia. No cases received octreotide.

DISCUSSION: The elimination half-life of insulin was relatively short in our study compared to previous reports and was not impacted by insulin dosage or duration, or kidney disease. There was endogenous insulin release despite hyperinsulinaemia, and C-peptide concentrations were mostly in established reference ranges, suggesting that dextrose supplementation was mostly not excessive. Resolution of hyperinsulinaemia typically occurred within 24 h of discontinuing high-dose insulin. During dextrose weaning, measuring serial C-peptide concentrations may identify excessive carbohydrate administration. Future research should assess how comorbidities such as diabetes mellitus and kidney disease influence insulin clearance.

CONCLUSIONS: This study identified a shorter insulin elimination half-life after discontinuing high-dose insulin than previously reported. Measuring serial insulin and C-peptide concentrations may guide clinical decisions, including dextrose weaning and confirm resolution of hyperinsulinaemia.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Nic Ionmhain Ú, Coulson L, Roberts DM, et al. Serial insulin and C-peptide concentrations following high-dose insulin for the treatment of drug poisoning: a consecutive case series. Clin Toxicol (Phila). 2026. PMID: 41642277. doi:10.1080/15563650.2026.2613033

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。